Pasteurellosis is a significant respiratory disease affecting swine populations worldwide, caused by the gram-negative bacterium Pasteurella multocida. Our company is at the forefront of vaccine and therapeutic development services, leveraging our expertise to advance the development of next-generation pasteurellosis solutions.
Introduction to Pasteurellosis
Pasteurellosis is a spectrum of infectious diseases caused by bacteria of the genus Pasteurella, most notably Pasteurella multocida. These Gram-negative facultative bacteria are responsible for significant morbidity and mortality in a variety of host species, including pigs, cattle, sheep, and poultry, as well as occasionally infecting humans through animal bites or scratches.
The types of pasteurellosis are generally classified based on the affected host and the disease manifestations. In pigs, for instance, the disease presents as progressive atrophic rhinitis (PAR), characterized by stunted development or total disappearance of the nasal turbinates. Other forms include pneumonia in various animals and fowl cholera in poultry.
Fig.1 The growth conditions of the gdhA derivative Pasteurella multocida B:2 in YDB medium. (Oslan S. N. H., et al., 2022)
Vaccine Development for Pasteurellosis
Live-Attenuated Vaccine
Live-attenuated vaccines use a weakened form of the bacteria that retains its ability to replicate but is less virulent, thus posing minimal risk to the host. An example is the mutant gdhA derivative of P. multocida B:2, which has shown promise as an attenuated live vaccine candidate.
Subunit and DNA Vaccines
Subunit vaccines focus on specific bacterial proteins, such as the outer membrane proteins or toxins, to stimulate an immune response. DNA vaccines involve the use of plasmids encoding antigens, which can be taken up by host cells to produce the antigen and elicit an immune response.
Inactivated Vaccines
Inactivated vaccines harness the power of inactivated bacteria or bacterial components to stimulate an immune response, offering a safe approach in vaccine development. To enhance their effectiveness, these vaccines may incorporate adjuvants to optimize their immunogenic properties.
Therapeutics Development for Pasteurellosis
Antibiotics such as ampicillin, ceftiofur, enrofloxacin, and tulathromycin have been used in the therapeutic of pasteurellosis. The choice of antibiotic may be influenced by the bacterial susceptibility profile, which can vary among different strains and regions. In addition to antibiotics, adjunct therapies may include immunostimulants or agents that modulate the host immune response to enhance the clearance of the bacteria.
Our organization offers comprehensive services for pasteurelosis therapy development. To explore further details, kindly click on the link below for additional information.
Our Services
Our services encompass a comprehensive approach to the development of vaccines and therapies for pasteurellosis. We leverage cutting-edge technologies and a deep understanding of the disease to offer solutions that are both innovative and effective.
Disease Models
- Pasteurella haemolytica Infection Mouse Models: Inbred C57 black mice
- Pasteurella multocida Infection Rat Models: Sprague-Dawley (SK/WDY) rats
- Pneumonic Pasteurellosis Infection Calves Models
Preclinical research is a cornerstone of our development services. We provide a range of preclinical research services designed to support the advancement of vaccines and therapies from the bench to the clinic. If you are interested in our services, please feel free to contact us.
References
- Oslan, Siti Nur Hazwani, et al. "Pasteurellosis vaccine commercialization: physiochemical factors for optimum production." Processes 10.7 (2022): 1248.
- Register, Karen B., and Susan L. Brockmeier. "Pasteurellosis." Diseases of swine (2019): 884-897.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
